{"transactions":[{"id":735051,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":361578,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are owned directly by BKJLAGG, LLC (\"BKJLAGG\") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium."}],"balance_after":834489,"derivative":{"underlying":"common stock, $0.01 par value per share","underlying_shares":361578},"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":735050,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":238422,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are owned directly by Domicilium Real Estate Fund III LP (the \"Fund\") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":0,"derivative":{"underlying":"common stock, $0.01 par value per share","underlying_shares":238422},"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":735049,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock, $0.01 par value per share","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":361578,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are owned directly by BKJLAGG, LLC (\"BKJLAGG\") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium."}],"balance_after":361578,"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":735048,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock, $0.01 par value per share","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":238422,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are owned directly by Domicilium Real Estate Fund III LP (the \"Fund\") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":238422,"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":743629,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":36319,"kind":"person","name":"Webster Stephen W","position":1,"cik":"0001438421","reported_name":"Webster Stephen W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T00:00:59.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":13587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":13587,"derivative":{"exercise_price":11,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13587},"source":{"system":"sec-edgar","filing":"0001193125-26-266279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526266279/ownership.xml","form_type":"4"}},{"id":743628,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T00:00:57.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":8590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":8590,"derivative":{"exercise_price":11,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":8590},"source":{"system":"sec-edgar","filing":"0001193125-26-266278","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526266278/ownership.xml","form_type":"4"}},{"id":743627,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39773,"kind":"person","name":"Kjellson Nina S","position":1,"cik":"0001381980","reported_name":"Kjellson Nina S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T00:00:56.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":13587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":13587,"derivative":{"exercise_price":11,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":13587},"source":{"system":"sec-edgar","filing":"0001193125-26-266276","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526266276/ownership.xml","form_type":"4"}},{"id":743626,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T00:00:54.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":328833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on September 19, 2025 and was subject to a performance-based vesting condition that was satisfied on June 10, 2026. The option will vest as to 1/36 on July 31, 2026, with the remaining options vesting in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuing service on each such vesting date."}],"balance_after":328833,"derivative":{"exercise_price":1.65,"expiration_date":"2035-09-19","underlying":"Common Stock","underlying_shares":328833},"source":{"system":"sec-edgar","filing":"0001193125-26-266277","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526266277/ownership.xml","form_type":"4"}},{"id":743625,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T00:00:53.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":4018,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":4018,"derivative":{"exercise_price":11,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":4018},"source":{"system":"sec-edgar","filing":"0001193125-26-266275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526266275/ownership.xml","form_type":"4"}},{"id":748687,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-06-05T14:44:56.000Z","date":"2026-05-27","kind":"other","planned":false,"acquired":true,"shares":113636,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\"), Domicilium Real Estate Fund III LP (the \"Fund\"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":238422,"derivative":{"underlying":"Common Stock, $0.01 par value per share","underlying_shares":113636},"source":{"system":"sec-edgar","filing":"0000919574-26-003845","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426003845/ownership.xml","form_type":"4"}},{"id":748686,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2026-06-05T14:44:56.000Z","date":"2026-05-27","kind":"other","planned":false,"acquired":false,"shares":113636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\"), Domicilium Real Estate Fund III LP (the \"Fund\"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000919574-26-003845","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426003845/ownership.xml","form_type":"4"}},{"id":759120,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-05-30T01:55:45.000Z","date":"2026-05-27","kind":"other","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the \"Partnership\"),\nexchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") have no expiration date and are exercisable at any time after the date of issuance. A holder of\nPre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding\nimmediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") have no expiration date and are exercisable at any time after the date of issuance. A holder of\nPre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding\nimmediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital\nLLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing\nthis Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that\nperson's pecuniary interest therein."}],"balance_after":30612243,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001104659-26-068440","document":"tm2615865-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465926068440/tm2615865-2_4seq1.xml","form_type":"4"}},{"id":759119,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":30038,"kind":"organization","name":"Coastlands Capital LP","position":1,"cik":"0002068530","reported_name":"Coastlands Capital LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-30T01:55:45.000Z","date":"2026-05-27","kind":"other","planned":false,"acquired":false,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Coastlands Capital LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Amended and Restated Pre-Funded Warrant to Purchase Common Stock, dated as of April 27, 2026, Coastlands Capital Partners LP (the \"Partnership\"),\nexchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Coastlands Capital LP (\"Coastlands\") and Coastlands Capital GP LLC (the \"General Partner\") are the investment adviser and general partner, respectively, of the Partnership. Coastlands Capital\nLLC (\"Coastlands GP\") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing\nthis Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that\nperson's pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-068440","document":"tm2615865-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465926068440/tm2615865-2_4seq1.xml","form_type":"4"}},{"id":787292,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-08T21:12:24.000Z","date":"2026-01-24","kind":"exercise","planned":false,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter."}],"balance_after":1875,"derivative":{"underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001193125-26-214983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214983/ownership.xml","form_type":"4"}},{"id":787291,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T21:12:24.000Z","date":"2025-09-19","kind":"grant","planned":false,"acquired":true,"shares":179854,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":179854,"derivative":{"exercise_price":0.15,"expiration_date":"2035-09-19","underlying":"Common Stock","underlying_shares":179854},"source":{"system":"sec-edgar","filing":"0001193125-26-214983","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214983/ownership.xml","form_type":"4"}},{"id":787290,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-08T21:12:24.000Z","date":"2026-01-24","kind":"exercise","planned":false,"acquired":true,"shares":1875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":14625,"source":{"system":"sec-edgar","filing":"0001193125-26-214983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214983/ownership.xml","form_type":"4"}},{"id":787312,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":false,"shares":260946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":3336144,"derivative":{"exercise_price":0.15,"expiration_date":"2035-09-19","underlying":"Common Stock","underlying_shares":260946},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787311,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Units","published_at":"2026-05-08T20:53:53.000Z","date":"2026-01-24","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787310,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2025-09-19","kind":"grant","planned":false,"acquired":true,"shares":3597090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":3597090,"derivative":{"exercise_price":0.15,"expiration_date":"2035-09-19","underlying":"Common Stock","underlying_shares":3597090},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787309,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2025-08-14","kind":"exercise","planned":false,"acquired":false,"shares":42790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2032-02-06","underlying":"Common Stock","underlying_shares":42790},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787308,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2025-08-14","kind":"exercise","planned":false,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option was granted on August 23, 2023 and was scheduled to vest subject to certain performance criteria, which the Board waived in connection with the exercise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2033-08-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787307,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2025-08-14","kind":"exercise","planned":false,"acquired":false,"shares":68700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter.  The Board accelerated vesting on the unvested portion in connection with the exercise."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":68700},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787306,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2025-08-14","kind":"exercise","planned":false,"acquired":false,"shares":60390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":0.0001,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":60390},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787305,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":68700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter.  The Board accelerated vesting on the unvested portion in connection with the exercise."}],"balance_after":68700,"derivative":{"exercise_price":0.0001,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":68700},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787304,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68700,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter.  The Board accelerated vesting on the unvested portion in connection with the exercise."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":68700},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787303,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":24810,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":24810,"derivative":{"exercise_price":0.0001,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":24810},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787302,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24810,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":1.41,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":24810},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787301,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":35580,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":35580,"derivative":{"exercise_price":0.0001,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":35580},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787300,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":35580,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":3.36,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":35580},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787299,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":42790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise."}],"balance_after":42790,"derivative":{"exercise_price":0.0001,"expiration_date":"2032-02-06","underlying":"Common Stock","underlying_shares":42790},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787298,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2024-10-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42790,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise."}],"balance_after":0,"derivative":{"exercise_price":18.4,"expiration_date":"2032-02-06","underlying":"Common Stock","underlying_shares":42790},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787297,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:53:53.000Z","date":"2022-02-06","kind":"grant","planned":false,"acquired":true,"shares":42790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise."}],"balance_after":42790,"derivative":{"exercise_price":18.4,"expiration_date":"2032-02-06","underlying":"Common Stock","underlying_shares":42790},"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787296,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-08T20:53:53.000Z","date":"2026-02-28","kind":"exercise","planned":false,"acquired":true,"shares":260946,"price":0.15,"value":39141.9,"ownership":{"direct":true},"balance_after":1672756,"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787295,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-08T20:53:53.000Z","date":"2026-01-24","kind":"exercise","planned":false,"acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1411810,"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787294,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-08T20:53:53.000Z","date":"2025-09-19","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") that was fully vested upon grant."}],"balance_after":1396810,"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787293,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-05-08T20:53:53.000Z","date":"2025-08-14","kind":"exercise","planned":false,"acquired":true,"shares":196880,"price":0.0001,"value":19.688,"ownership":{"direct":true},"balance_after":396810,"source":{"system":"sec-edgar","filing":"0001193125-26-214890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214890/ownership.xml","form_type":"4"}},{"id":787289,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-05-08T20:44:52.000Z","date":"2026-01-24","kind":"exercise","planned":false,"acquired":false,"shares":1875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested as to 50% on the first anniversary of January 24, 2024, and the remaining amount vested in two equal annual installments thereafter."}],"balance_after":1875,"derivative":{"underlying":"Common Stock","underlying_shares":1875},"source":{"system":"sec-edgar","filing":"0001193125-26-214815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214815/ownership.xml","form_type":"4"}},{"id":787288,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-08T20:44:52.000Z","date":"2025-09-19","kind":"grant","planned":false,"acquired":true,"shares":395680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments for 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":395680,"derivative":{"exercise_price":0.15,"expiration_date":"2035-09-19","underlying":"Common Stock","underlying_shares":395680},"source":{"system":"sec-edgar","filing":"0001193125-26-214815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214815/ownership.xml","form_type":"4"}},{"id":787287,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-08T20:44:52.000Z","date":"2026-01-24","kind":"exercise","planned":false,"acquired":true,"shares":1875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":15567,"source":{"system":"sec-edgar","filing":"0001193125-26-214815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000119312526214815/ownership.xml","form_type":"4"}},{"id":1293352,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-28T22:37:18.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":30000,"derivative":{"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-25-006784","document":"tm254730-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006784/tm254730-4_4seq1.xml","form_type":"4"}},{"id":1293351,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-28T22:37:18.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":199930,"source":{"system":"sec-edgar","filing":"0001104659-25-006784","document":"tm254730-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006784/tm254730-4_4seq1.xml","form_type":"4"}},{"id":1293348,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-28T22:36:23.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001104659-25-006783","document":"tm254730-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006783/tm254730-3_4seq1.xml","form_type":"4"}},{"id":1293347,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-28T22:36:23.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15750,"source":{"system":"sec-edgar","filing":"0001104659-25-006783","document":"tm254730-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006783/tm254730-3_4seq1.xml","form_type":"4"}},{"id":1293346,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":68206,"kind":"person","name":"Androski Lindsay","position":1,"cik":"0001936604","reported_name":"Androski Lindsay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-28T22:35:27.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001104659-25-006782","document":"tm254730-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006782/tm254730-2_4seq1.xml","form_type":"4"}},{"id":1293345,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":68206,"kind":"person","name":"Androski Lindsay","position":1,"cik":"0001936604","reported_name":"Androski Lindsay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-28T22:35:27.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15750,"source":{"system":"sec-edgar","filing":"0001104659-25-006782","document":"tm254730-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006782/tm254730-2_4seq1.xml","form_type":"4"}},{"id":1293344,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-01-28T22:34:29.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":3750,"derivative":{"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001104659-25-006781","document":"tm254730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006781/tm254730-1_4seq1.xml","form_type":"4"}},{"id":1293343,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-28T22:34:29.000Z","date":"2025-01-24","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16692,"source":{"system":"sec-edgar","filing":"0001104659-25-006781","document":"tm254730-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465925006781/tm254730-1_4seq1.xml","form_type":"4"}},{"id":1385141,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:02:21.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":12942,"source":{"system":"sec-edgar","filing":"0001104659-24-109525","document":"tm2426349-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924109525/tm2426349-5_4seq1.xml","form_type":"4"}},{"id":1385140,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":68206,"kind":"person","name":"Androski Lindsay","position":1,"cik":"0001936604","reported_name":"Androski Lindsay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:01:56.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-24-109524","document":"tm2426349-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924109524/tm2426349-4_4seq1.xml","form_type":"4"}},{"id":1385138,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:01:36.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This restricted stock grant was made pursuant to the Issuer's 2018 Equity Incentive Plan and vests as to 50% of the shares on October 16, 2025 and in 12 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0001104659-24-109523","document":"tm2426349-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924109523/tm2426349-3_4seq1.xml","form_type":"4"}},{"id":1385137,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-10-17T20:01:12.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This restricted stock award was made under the Issuer's 2018 Equity Incentive Plan and vests as to 25% on October 16, 2025 and in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":169930,"source":{"system":"sec-edgar","filing":"0001104659-24-109519","document":"tm2426349-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924109519/tm2426349-2_4seq1.xml","form_type":"4"}},{"id":1669876,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-01-26T21:33:26.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-24-007294","document":"tm244260-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924007294/tm244260-4_4seq1.xml","form_type":"4"}},{"id":1669875,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-01-26T21:33:02.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-24-007293","document":"tm244260-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924007293/tm244260-3_4seq1.xml","form_type":"4"}},{"id":1669874,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":68206,"kind":"person","name":"Androski Lindsay","position":1,"cik":"0001936604","reported_name":"Androski Lindsay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-01-26T21:32:33.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the\nReporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the\nReporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-24-007291","document":"tm244260-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924007291/tm244260-2_4seq1.xml","form_type":"4"}},{"id":1669873,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2024-01-26T21:32:14.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-24-007290","document":"tm244260-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465924007290/tm244260-1_4seq1.xml","form_type":"4"}},{"id":2040583,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-31T21:12:17.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":2859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":2859,"derivative":{"exercise_price":4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":2859},"source":{"system":"sec-edgar","filing":"0001104659-23-008604","document":"tm234943-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923008604/tm234943-4_4seq1.xml","form_type":"4"}},{"id":2040582,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-31T21:09:58.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":2859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":2859,"derivative":{"exercise_price":4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":2859},"source":{"system":"sec-edgar","filing":"0001104659-23-008601","document":"tm234943-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923008601/tm234943-3_4seq1.xml","form_type":"4"}},{"id":2040581,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-31T21:08:40.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":2859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":2859,"derivative":{"exercise_price":4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":2859},"source":{"system":"sec-edgar","filing":"0001104659-23-008599","document":"tm234943-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923008599/tm234943-2_4seq1.xml","form_type":"4"}},{"id":2040580,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":68206,"kind":"person","name":"Androski Lindsay","position":1,"cik":"0001936604","reported_name":"Androski Lindsay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-31T21:07:15.000Z","date":"2023-01-30","kind":"grant","acquired":true,"shares":2859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":2859,"derivative":{"exercise_price":4,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":2859},"source":{"system":"sec-edgar","filing":"0001104659-23-008597","document":"tm234943-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923008597/tm234943-1_4seq1.xml","form_type":"4"}},{"id":2043940,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-27T21:04:02.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":68700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":68700,"derivative":{"exercise_price":4.27,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":68700},"source":{"system":"sec-edgar","filing":"0001104659-23-007511","document":"tm234565-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923007511/tm234565-2_4seq1.xml","form_type":"4"}},{"id":2043939,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":117604,"kind":"person","name":"MODUR VIJAY","position":1,"cik":"0001854082","reported_name":"MODUR VIJAY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF R&D"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-27T21:02:53.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date."}],"balance_after":30000,"derivative":{"exercise_price":4.27,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001104659-23-007510","document":"tm234565-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923007510/tm234565-1_4seq1.xml","form_type":"4"}},{"id":2212503,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":68206,"kind":"person","name":"Androski Lindsay","position":1,"cik":"0001936604","reported_name":"Androski Lindsay","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-07-07T01:50:36.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on July 1, 2023 and the remainder in twelve (12) equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":0.25,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-22-077837","document":"tm2220578-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922077837/tm2220578-1_4seq1.xml","form_type":"4"}},{"id":2228492,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:29:27.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072191","document":"tm2218714-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072191/tm2218714-8_4seq1.xml","form_type":"4"}},{"id":2228491,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":126068,"kind":"person","name":"Veinrib Gadi","position":1,"cik":"0001726015","reported_name":"Veinrib Gadi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:28:59.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072189","document":"tm2218714-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072189/tm2218714-7_4seq1.xml","form_type":"4"}},{"id":2228490,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":53564,"kind":"person","name":"Seehra Jasbir","position":1,"cik":"0001732369","reported_name":"Seehra Jasbir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:28:16.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072188","document":"tm2218714-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072188/tm2218714-6_4seq1.xml","form_type":"4"}},{"id":2228489,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:27:49.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072187","document":"tm2218714-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072187/tm2218714-5_4seq1.xml","form_type":"4"}},{"id":2228488,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":112513,"kind":"person","name":"PAREKH RAJESH B","position":1,"cik":"0001429930","reported_name":"PAREKH RAJESH B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:27:06.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072185","document":"tm2218714-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072185/tm2218714-4_4seq1.xml","form_type":"4"}},{"id":2228487,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:26:16.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072179","document":"tm2218714-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072179/tm2218714-3_4seq1.xml","form_type":"4"}},{"id":2228486,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:24:38.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072176","document":"tm2218714-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072176/tm2218714-2_4seq1.xml","form_type":"4"}},{"id":2228485,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":126067,"kind":"person","name":"Avnur Zafrira","position":1,"cik":"0001726049","reported_name":"Avnur Zafrira","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-17T12:23:51.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal installments thereafter."}],"balance_after":20000,"derivative":{"exercise_price":0.26,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-072175","document":"tm2218714-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922072175/tm2218714-1_4seq1.xml","form_type":"4"}},{"id":2486683,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-12-03T22:16:42.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":37695,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37695},"source":{"system":"sec-edgar","filing":"0001415889-21-005694","document":"form4-12032021_021230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005694/form4-12032021_021230.xml","form_type":"4"}},{"id":2486682,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-03T22:16:42.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":37695,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":37695,"source":{"system":"sec-edgar","filing":"0001415889-21-005694","document":"form4-12032021_021230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005694/form4-12032021_021230.xml","form_type":"4"}},{"id":2486681,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Restricted Stock Units","published_at":"2021-12-03T22:15:25.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":279158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":279158},"source":{"system":"sec-edgar","filing":"0001415889-21-005693","document":"form4-12032021_021217.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005693/form4-12032021_021217.xml","form_type":"4"}},{"id":2486680,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2021-12-03T22:15:25.000Z","date":"2021-12-01","kind":"tax_withholding","acquired":false,"shares":81933,"price":0.72,"value":58991.76,"ownership":{"direct":true},"balance_after":197225,"source":{"system":"sec-edgar","filing":"0001415889-21-005693","document":"form4-12032021_021217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005693/form4-12032021_021217.xml","form_type":"4"}},{"id":2486679,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2021-12-03T22:15:25.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":279158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."}],"balance_after":279158,"source":{"system":"sec-edgar","filing":"0001415889-21-005693","document":"form4-12032021_021217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005693/form4-12032021_021217.xml","form_type":"4"}},{"id":2486678,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":117604,"kind":"person","name":"MODUR VIJAY","position":1,"cik":"0001854082","reported_name":"MODUR VIJAY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF R&D"}}],"security":"Restricted Stock Units","published_at":"2021-12-03T22:14:26.000Z","date":"2021-12-01","kind":"exercise","acquired":false,"shares":219326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":219326},"source":{"system":"sec-edgar","filing":"0001415889-21-005692","document":"form4-12032021_021220.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005692/form4-12032021_021220.xml","form_type":"4"}},{"id":2486677,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":117604,"kind":"person","name":"MODUR VIJAY","position":1,"cik":"0001854082","reported_name":"MODUR VIJAY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF R&D"}}],"security":"Common Stock","published_at":"2021-12-03T22:14:26.000Z","date":"2021-12-01","kind":"tax_withholding","acquired":false,"shares":64373,"price":0.72,"value":46348.56,"ownership":{"direct":true},"balance_after":154953,"source":{"system":"sec-edgar","filing":"0001415889-21-005692","document":"form4-12032021_021220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005692/form4-12032021_021220.xml","form_type":"4"}},{"id":2486676,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":117604,"kind":"person","name":"MODUR VIJAY","position":1,"cik":"0001854082","reported_name":"MODUR VIJAY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF R&D"}}],"security":"Common Stock","published_at":"2021-12-03T22:14:26.000Z","date":"2021-12-01","kind":"exercise","acquired":true,"shares":219326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock."}],"balance_after":219326,"source":{"system":"sec-edgar","filing":"0001415889-21-005692","document":"form4-12032021_021220.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005692/form4-12032021_021220.xml","form_type":"4"}},{"id":2490975,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":90815,"kind":"person","name":"Geffken Daniel E.","position":1,"cik":"0001314756","reported_name":"Geffken Daniel E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"INTERIM CFO"}}],"security":"Common Stock","published_at":"2021-12-01T16:06:56.000Z","date":"2021-11-29","kind":"purchase","acquired":true,"shares":50000,"price":0.72,"value":36000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Price represents the average purchase price per share."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001415889-21-005600","document":"form4-12012021_081251.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921005600/form4-12012021_081251.xml","form_type":"4"}},{"id":2621533,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":114794,"kind":"person","name":"Belloff Neil S.","position":1,"cik":"0001741670","reported_name":"Belloff Neil S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, GENERAL COUNSEL &CORP SEC"}}],"security":"Restricted Stock Units","published_at":"2021-07-31T00:32:44.000Z","date":"2021-07-30","kind":"exercise","acquired":false,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction."}],"balance_after":9375,"derivative":{"underlying":"Common Stock","underlying_shares":1563},"source":{"system":"sec-edgar","filing":"0001415889-21-003750","document":"form4-07302021_050735.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921003750/form4-07302021_050735.xml","form_type":"4"}},{"id":2621532,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":114794,"kind":"person","name":"Belloff Neil S.","position":1,"cik":"0001741670","reported_name":"Belloff Neil S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, GENERAL COUNSEL &CORP SEC"}}],"security":"Common Stock","published_at":"2021-07-31T00:32:44.000Z","date":"2021-07-30","kind":"tax_withholding","acquired":false,"shares":459,"price":1.32,"value":605.88,"ownership":{"direct":true},"balance_after":32699,"source":{"system":"sec-edgar","filing":"0001415889-21-003750","document":"form4-07302021_050735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921003750/form4-07302021_050735.xml","form_type":"4"}},{"id":2621531,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":114794,"kind":"person","name":"Belloff Neil S.","position":1,"cik":"0001741670","reported_name":"Belloff Neil S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, GENERAL COUNSEL &CORP SEC"}}],"security":"Common Stock","published_at":"2021-07-31T00:32:44.000Z","date":"2021-07-30","kind":"exercise","acquired":true,"shares":1563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock."}],"balance_after":33158,"source":{"system":"sec-edgar","filing":"0001415889-21-003750","document":"form4-07302021_050735.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921003750/form4-07302021_050735.xml","form_type":"4"}},{"id":2695733,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":114794,"kind":"person","name":"Belloff Neil S.","position":1,"cik":"0001741670","reported_name":"Belloff Neil S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, GENERAL COUNSEL &CORP SEC"}}],"security":"Restricted Stock Units","published_at":"2021-05-26T20:10:14.000Z","date":"2021-05-25","kind":"exercise","acquired":false,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances."}],"balance_after":68750,"derivative":{"underlying":"Common Stock","underlying_shares":6250},"source":{"system":"sec-edgar","filing":"0001415889-21-002682","document":"form4-05262021_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002682/form4-05262021_040501.xml","form_type":"4"}},{"id":2695732,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":114794,"kind":"person","name":"Belloff Neil S.","position":1,"cik":"0001741670","reported_name":"Belloff Neil S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, GENERAL COUNSEL &CORP SEC"}}],"security":"Common Stock","published_at":"2021-05-26T20:10:14.000Z","date":"2021-05-25","kind":"tax_withholding","acquired":false,"shares":1835,"price":1.39,"value":2550.65,"ownership":{"direct":true},"balance_after":31595,"source":{"system":"sec-edgar","filing":"0001415889-21-002682","document":"form4-05262021_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002682/form4-05262021_040501.xml","form_type":"4"}},{"id":2695731,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":114794,"kind":"person","name":"Belloff Neil S.","position":1,"cik":"0001741670","reported_name":"Belloff Neil S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO, GENERAL COUNSEL &CORP SEC"}}],"security":"Common Stock","published_at":"2021-05-26T20:10:14.000Z","date":"2021-05-25","kind":"exercise","acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock."}],"balance_after":33430,"source":{"system":"sec-edgar","filing":"0001415889-21-002682","document":"form4-05262021_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002682/form4-05262021_040501.xml","form_type":"4"}},{"id":2703645,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39774,"kind":"person","name":"Walts Alan Edmund","position":1,"cik":"0001853544","reported_name":"Walts Alan Edmund","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:11:12.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."}],"balance_after":3334,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001415889-21-002616","document":"form4-05202021_040547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002616/form4-05202021_040547.xml","form_type":"4"}},{"id":2703644,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":112513,"kind":"person","name":"PAREKH RAJESH B","position":1,"cik":"0001429930","reported_name":"PAREKH RAJESH B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:11:02.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP."}],"balance_after":3334,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001415889-21-002615","document":"form4-05202021_040542.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002615/form4-05202021_040542.xml","form_type":"4"}},{"id":2703643,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":126067,"kind":"person","name":"Avnur Zafrira","position":1,"cik":"0001726049","reported_name":"Avnur Zafrira","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:55.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002613","document":"form4-05202021_040532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002613/form4-05202021_040532.xml","form_type":"4"}},{"id":2703642,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":40939,"kind":"person","name":"Nussbaum Ran","position":1,"cik":"0001609805","reported_name":"Nussbaum Ran","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:50.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002614","document":"form4-05202021_040537.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002614/form4-05202021_040537.xml","form_type":"4"}},{"id":2703641,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74168,"kind":"person","name":"Kariv Tomer","position":1,"cik":"0001568077","reported_name":"Kariv Tomer","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:46.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002612","document":"form4-05202021_040528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002612/form4-05202021_040528.xml","form_type":"4"}},{"id":2703640,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":126068,"kind":"person","name":"Veinrib Gadi","position":1,"cik":"0001726015","reported_name":"Veinrib Gadi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:37.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002611","document":"form4-05202021_040518.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002611/form4-05202021_040518.xml","form_type":"4"}},{"id":2703639,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":25378,"kind":"person","name":"Rubin Steven D","position":1,"cik":"0001381874","reported_name":"Rubin Steven D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:27.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002609","document":"form4-05202021_040501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002609/form4-05202021_040501.xml","form_type":"4"}},{"id":2703638,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":53564,"kind":"person","name":"Seehra Jasbir","position":1,"cik":"0001732369","reported_name":"Seehra Jasbir","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T20:10:25.000Z","date":"2021-05-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the \"Cliff Vesting Date\"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date."}],"balance_after":20000,"derivative":{"exercise_price":1.48,"expiration_date":"2031-05-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-21-002610","document":"form4-05202021_040512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002610/form4-05202021_040512.xml","form_type":"4"}},{"id":2708658,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":117604,"kind":"person","name":"MODUR VIJAY","position":1,"cik":"0001854082","reported_name":"MODUR VIJAY","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"HEAD OF R&D"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-18T21:48:03.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":496204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan in accordance with the anti-dilution provisions of the Reporting Person's employment agreement in connection with a Qualifying Financing as defined therein. The stock options vest and become exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction."}],"balance_after":496204,"derivative":{"exercise_price":1.41,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":496204},"source":{"system":"sec-edgar","filing":"0001415889-21-002555","document":"form4-05182021_020547.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002555/form4-05182021_020547.xml","form_type":"4"}},{"id":2708657,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":39772,"kind":"person","name":"Aggarwal Sumit","position":1,"cik":"0001854362","reported_name":"Aggarwal Sumit","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-18T21:45:58.000Z","date":"2021-05-18","kind":"grant","acquired":true,"shares":992409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan in accordance with the anti-dilution provisions of the Reporting Person's employment agreement in connection with a Qualifying Financing as defined therein. The stock options vest and become exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction."}],"balance_after":992409,"derivative":{"exercise_price":1.41,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":992409},"source":{"system":"sec-edgar","filing":"0001415889-21-002554","document":"form4-05182021_050501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588921002554/form4-05182021_050501.xml","form_type":"4"}},{"id":2710682,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":112513,"kind":"person","name":"PAREKH RAJESH B","position":1,"cik":"0001429930","reported_name":"PAREKH RAJESH B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T13:22:11.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":2381890,"price":1.35,"value":3215551.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein."}],"balance_after":4827129,"source":{"system":"sec-edgar","filing":"0001104659-21-067516","document":"tm2116620d4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067516/tm2116620d4_4.xml","form_type":"4"}},{"id":2710681,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":112513,"kind":"person","name":"PAREKH RAJESH B","position":1,"cik":"0001429930","reported_name":"PAREKH RAJESH B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T13:22:11.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":84776,"price":1.35,"value":114447.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein."}],"balance_after":171807,"source":{"system":"sec-edgar","filing":"0001104659-21-067516","document":"tm2116620d4_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067516/tm2116620d4_4.xml","form_type":"4"}},{"id":2710686,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":592592,"price":1.35,"value":799999.2,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.(\"Late Stage Fund\"). Pontifax Late Stage GP Ltd. (\"Late Stage GP\"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":616592,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710685,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":1422222,"price":1.35,"value":1919999.7,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents shares of the Issuer held by Pontifax (China) IV L.P. (\"China IV\"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":1989551,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}},{"id":2710684,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":74162,"kind":"organization","name":"Pontifax Management 4 G.P. (2015) Ltd.","position":1,"cik":"0001726334","reported_name":"Pontifax Management 4 G.P. (2015) Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74165,"kind":"organization","name":"Pontifax (China) IV L.P.","position":2,"cik":"0001726030","reported_name":"Pontifax (China) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74164,"kind":"organization","name":"Pontifax (Cayman) IV L.P.","position":3,"cik":"0001726029","reported_name":"Pontifax (Cayman) IV L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":74163,"kind":"organization","name":"Pontifax (Israel) IV, L.P.","position":4,"cik":"0001726039","reported_name":"Pontifax (Israel) IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139359,"kind":"organization","name":"Pontifax IV GP L.P.","position":5,"cik":"0001726353","reported_name":"Pontifax IV GP L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T11:03:28.000Z","date":"2021-05-13","kind":"purchase","acquired":true,"shares":2630487,"price":1.35,"value":3551157.45,"ownership":{"direct":false,"nature":"By Pontifax Investment Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. (\"Israel IV\"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."}],"balance_after":3679797,"source":{"system":"sec-edgar","filing":"0001104659-21-067336","document":"tm2116620d3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921067336/tm2116620d3_4.xml","form_type":"4"}}],"next_cursor":"2021-05-17T11:03:28.000000Z,2710684"}